Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
August 7, 2025
Earnings Call Speaker Segments
Corinne Franklin
executiveThanks, and good afternoon, everybody. We appreciate you being with us today. Joining us on this call are Howard W. Robin, who serves as our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research & Development Officer; and Sandra Gardiner, our Chief Financial Officer. Dr. Brian Kotzin, our Chief Medical Officer, will also be on hand for the Q&A portion; during today's call, we anticipate making forward-looking statements about our business, including statements about the therapeutic potential of and future development and regulatory plans for REZPEG and our other drug candidates, the timing and plans for future clinical data presentations, and other statements about the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, many of which lie outside our control. Our actual results could differ materially from those statements. Key risks and uncertainties appear in our Form 10-Q filed on May 9, 2025, which is available at SEC.gov. We assume no obligation to update any of these forward-looking statements, whether due to new information, future development, or otherwise. A webcast of this call can be accessed on the IR page of Nektar's website at nektar.com. Having said that, I'd like to turn the call over to our President and CEO, Howard Robin.
Howard Robin
executiveThank you, Corinne, and hello everyone on this call this afternoon. The second quarter of 2025 marked a major turning point for Nektar. In June, we presented very strong early-stage results in atopic dermatitis from rezpegaldesleukin, our most advanced clinical candidate, also known as REZPEG. These findings establish REZPEG as potentially the first therapy of its kind, offering a novel T regulatory mechanism for individuals living with this long-term, relapsing inflammatory condition of the skin. Returning to 2023, we took the courageous step of building our entire pipeline around T regulatory cell science. At its core, this approach involves activating Tregs through a range of methods to reestablish a proper equilibrium between T effector cells and T regulatory cells, thereby achieving immune system homeostasis. At that stage, what we wanted to demonstrate was that this key pathway could potentially provide an entirely novel approach to addressing autoimmune and inflammatory conditions by mimicking the way our immune system naturally shuts down inflammation. Then, in October 2023, we kicked off a phase II-B study involving 400 patients to evaluate REZPEG in those suffering from moderate to severe atopic dermatitis, since the early proof-of-concept results in patients had appeared encouraging back then. For our second indication, we decided to run a phase II-B trial in alopecia areata. In that disease context, a deficiency in underlying T regulatory cells creates a well-documented imbalance between T effector cells and T regulatory cells, leading to hair loss in these individuals. The REZOLVE-AD data that came out not long ago also serve as confirmation of how Nektar does something new in reaching Tregs through the IL-2 pathway, using a molecular design that stands apart from what competitors have done. Other players trying to get at IL-2 have put their focus on engineering muteins, and in our view that is what slowed their progress both in recent times and over many years. We took a different path — one that is simple and elegant — reaching Treg biology through an IL-2 that uses the native sequence, followed by PEGylation. That chemistry is well established, having won approval for more than 30 biologics along with small molecules across the past several decades, and Nektar had a hand in a large number of them. With FDA Fast Track status now in hand for atopic dermatitis as well as alopecia areata, we can pick up the pace and work alongside the FDA to map out the speediest possible regulatory routes. That decision highlights how substantial an unmet need still exists in atopic dermatitis and alopecia areata for treatments built on new mechanisms of action. Our first-in-class novel Treg mechanism, we believe, leaves us strongly positioned, and it is set to begin phase III development in 2026. Turning to the atopic dermatitis market: in the eight years since dupixent's launch, it has grown to approximately $15 billion in U.S. sales, and projections suggest it may approach $30 billion by 2033. Findings from our latest market study suggest that doctors would choose REZPEG for atopic dermatitis patients whether or not they've previously used biologics, and we intend to build a phase III trial that seizes this distinctive opening before us. At present, treatments based on IL-13 represent the leading strategy in this area, but about 50% of patients fail to respond via that pathway. Additionally, those IL-13 treatments come with a recognized chance of adverse events, such as conjunctivitis and infection, which patients may find hard to tolerate. Because of these obstacles, a significant opportunity is available for REZPEG, given its fast onset of easy response together with relief from itch. In this landscape, REZPEG is set up to occupy a differentiated position. As J.Z. will walk through in greater detail, the Phase III plan we've built is meant to secure a broad label covering both naive and experienced patients, which would let RESZPEG claim a substantial portion of the atopic dermatitis market as it grows into the multibillion dollar range. Because historically there has been a very strong correlation between positive phase II-B results and later approvals in atopic dermatitis, our focus is squarely on getting into phase III quickly, and readiness work is already moving forward. The $115 million equity financing we closed in June was oversubscribed, and it has made our financial standing even more solid. This allows us to complete the essential phase III enabling CMC work along with regulatory planning, which means REZPEG should be ready for phase III during the first half of 2026. In addition, that financing lets us extend our cash runway into 2027. Looking ahead, the REZOLVE-AD trial that is currently running will generate more data in Q1 of 2026, and we anticipate that this will help further clarify how durable and deep the response to RESZPEG is through week 52. Later in the year, at a medical conference, we plan to share findings on how patients reported feeling—specifically around quality of life and symptoms—gathered during the 16-week induction phase. That session will also include a scheduled analysis of results for people who received placebo in induction and subsequently moved into an escape treatment group. As this fresh analysis approaches, we're keen to find out if EASI improvements grow larger when REZPEG is given beyond the 16-week induction window. J. Z. will soon walk everyone through this important data set in greater detail. Separately, we still expect to disclose results in December of this year from the phase II-B trial in alopecia areata. This shows we're going after the root cause of hair loss in people with alopecia. If we get another favorable outcome there, it would prove REZPEG works through a brand-new pathway in dermatology, a space where only one mechanism—JAK inhibitors—has won approval. Those carry several familiar black box warnings and are associated with frequent relapses after patients stop taking them. By 2033, forecasts value the alopecia areata treatment market at $2 billion, and in our view, a fresh mechanism like REZPEG might capture a substantial portion of that. I'll now hand the call to J. Z; for more specifics on REZPEG and our earlier pipeline programs.
Jonathan Zalevsky
executiveHoward, thanks, and I appreciate everyone joining the call today. First off, I want to take you back through the main points from our webcast on June 24th, when we shared top line data on 16-week induction from the ongoing Phase 2b trial called REZOLVE-AD. In REZOLVE-AD, 393 patients were enrolled, and the trial is evaluating REZPEG (rezpegaldesleukin) in biologic-naive individuals suffering from moderate to severe atopic dermatitis. For the primary endpoint, the study achieved statistical significance on mean percentage change in EASI score from baseline across every REZPEG arm compared with placebo at week 16. On EASI-50, EASI-75, and BSA, all three REZPEG arms hit significance. Significance was reached on vIGA-AD and itch NRS for the every two weeks regimens, and statistical significance on EASI-90 was also achieved by the 24 microgram per kilogram every two weeks high dose. We observed both EASI reduction and the extent of itch improvement following just the first few doses of REZPEG, which we believe may genuinely set it apart from other systemic therapies when it comes to a faster onset of action. Additionally, REZPEG's safety profile in the phase II-B setting matched what has previously been reported from other REZPEG clinical studies, and we saw no increase in risk or incidence of conjunctivitis, oral herpes, or oral ulcers, unlike what is observed with other agents either approved or in development. The maintenance period of the study is still underway, and we anticipate sharing top line results for 52 weeks of dosing for the 36-week Q4 week and Q12 week maintenance regimens, along with the Q2 week escape arm regimen, in Q1 2026. As Howard noted earlier, we look forward to presenting additional differentiating endpoints from the induction phase of REZOLVE-AD at a medical meeting this fall. Among these are quality of life assessments, including sleep quality, skin pain reduction, overall patient experience, and other important metrics that matter to patients fighting atopic dermatitis. During that presentation, we also plan a data cut examining patients who have had 24 weeks of treatment with the highest dose induction regimen of REZPEG 24 microgram per kg Q2 week. You may remember that our study design permitted patients from induction whose EASI scores were below 50 to move into a treatment escape arm for as long as 36 weeks. As we reported in June, 42 patients in the placebo arm during the 16-week induction had a week 16 EASI score worse than EASI-50 and entered this escape treatment arm. These patients constitute a true crossover population for studying the extended duration of rezpegaldesleukin dosing. By this fall, we expect that over half of the patients in this crossover cohort will have completed 24 weeks of treatment. With this new upcoming data cut, we are eager to see whether EASI responses can deepen with continued REZPEG treatment beyond week 16 and out to week 24. With IL-13 agents, you don't see this—their effect usually plateaus once induction wraps up. That's why we're enthusiastic about what's possible here: the REZPEG data we've reported at 16 weeks lines up with what OX40 agents show after 24 weeks, yet itch response and EASI 75 come on faster than with those drugs. Back in February, we told you about receiving Fast Track designation for REZPEG in adults and pediatric patients aged 12 and up who have moderate to severe atopic dermatitis that isn't adequately controlled by topical prescription therapies, or where such therapies aren't advisable. Howard mentioned it, and yes—Phase 3 readiness work and clinical trial design planning are underway as we get set for an end of phase II meeting with the FDA later this year. Our aim is to have REZPEG ready to kick off its first phase III study during the first half of 2026. Right now we're actively assessing multiple design pathways, among them options giving a clear line of sight to approval of rezpegaldesleukin in patients regardless of whether they're biologic-naive or biologic-experienced. Once we've had that end of phase II meeting with the FDA later this year, we'll lock in the trial design. Given the robust REZOLVE-AD data confirming the optimal induction dose and target patient population, our focus is on keeping momentum going so REZPEG advances in atopic dermatitis as fast as we can. Turning now to alopecia areata: enrollment for the phase II-B REZOLVE-AA trial wrapped up in February, and we look forward to sharing top-line results in December. In that study, for patients with severe to very severe alopecia areata, REZPEG is under evaluation at 18 micrograms per kilogram or 24 micrograms per kilogram dosed every two weeks, compared against placebo. 94 patients in total were enrolled, and the week 36 primary endpoint is mean percent improvement in SALT score. Remember, alopecia areata is another dermal disease—so what we've seen in atopic dermatitis, backed up by an earlier separate psoriasis study, suggests this T regulatory cell mechanism carries strong efficacy signals in dermatological settings. In alopecia areata, the patient's immune system mistakenly attacks the hair follicle, disrupting the body's normal capacity to keep and grow hair, which leads to severe hair loss and a lack of regrowth. The root cause, we know, is an imbalance between T effector cells and T regulatory cells around the hair follicle; that imbalance causes T effector cells to attack and damage the hair follicle while preventing Tregs from signaling to hair stem cells and promoting their function. By stimulating T regulatory cells, we're aiming to overcome how the disease develops and bring immune homeostasis back. During REZOLVE-AA, a variety of secondary endpoints are also going to be evaluated by us, such as the percentage of subjects experiencing a reduction of at least 50% in SALT by week 36 along with additional time points that get assessed, plus the endpoints required for regulatory approval in phase III trials. For the SALT 20 and SALT 10 responder analyses that take place after the week 36 evaluations, those patients failing to reach a SALT score at or below 20 yet showing meaningful hair regrowth across those 36 weeks can sign up for a treatment extension lasting 16 weeks, giving us a subset of individuals who will receive therapy for a full 52 weeks. Shifting to type 1 diabetes, one more autoimmune condition in which REZPEG holds significant promise as a Treg therapy, our belief is that REZPEG may be capable of slowing the ongoing destruction of beta cells that produce insulin, the very cells attacked by a patient's hyperactive immune system in this illness. As was shared earlier, an investigator-sponsored phase II clinical trial is being sponsored and run by TrialNet, testing REZPEG in 66 individuals with newly diagnosed type 1 diabetes; thanks to funding from the NIH, TrialNet is expected by us to launch this research before the year concludes. Lastly, NKTR-0165, the TNFR2 agonist antibody initiative we are developing, is moving ahead through IND enabling work, targeting entry into the clinic during 2026. Agonism at TNFR2 boosts Treg functionality together with preserving the ability to maintain Treg lineage, particularly within non-lymphoid tissue compartments. Preclinical findings from this effort were first shared a year ago at EULAR, showing that NKTR-0165 possesses extremely high selectivity for signaling via TNFR2 on Tregs and for strengthening their immunoregulatory phenotype; additionally, it was demonstrated that the agonist our team identified can signal through the multimeric TNFR2 receptor functioning as a single-arm monovalent antibody, and to our knowledge this is the sole antibody within this category under development possessing such a characteristic. Given that the TNFR2 epitope our team identified is capable of operating as a single-arm agonist, we have taken this breakthrough and built it into a platform of bispecific and multispecific assemblies. The initial candidate out of that pipeline, NKTR-0166, combines TNFR2 agonism with a well-validated target, producing a molecule featuring a novel mechanism of action and remarkably innovative properties. Further updates regarding NKTR-0166 and additional agents are something we look forward to sharing over the next several quarters. At this point I'll hand things over to Sandra for the financial discussion.
Sandra Gardiner
executiveThanks, J.Z., and good afternoon to all of you. During this call, I'll quickly go over the financial results for the quarter and provide updates to the guidance we've given for 2025; as of the close of 2025's second quarter, we held $175.9 million in cash and investments, with no debt appearing on our balance sheet. As Howard mentioned previously, we finished a secondary public offering on July 2, 2025, which brought in roughly $107.5 million in net proceeds; through this raise, our financial position grew even stronger, pushing our cash runway out to the first quarter of 2027, and it also lets us put money into our REZPEG program so it can move forward to phase III, plus continue developing NKTR-0165 and NKTR-0166, the TNFR2 agonist antibody candidates we have. Our larger 2025 plan covers startup activities for REZPEG's phase III clinical work and locking in extra manufacturing capacity for REZPEG. We anticipate finishing the year with somewhere around $180 million to $185 million in cash and investments. Moving to the income statement, non-cash royalty revenue came to $11.2 million during 2025's second quarter; for the entire year, we continue to project that non-cash royalty revenue will reach roughly $40 million. R&D expense for 2025's second quarter was $29.9 million, and our current expectation for the full year is that R&D expense will fall somewhere between $125 million and $130 million, which includes about $5 million to $10 million in non-cash depreciation along with stock-based compensation expense. G&A expense came in at $17.1 million for the second quarter. For the whole of 2025, we now anticipate G&A landing between $70 million and $75 million, which includes roughly $5 million to $10 million of non-cash depreciation and stock-based compensation expense; the bump in this guidance comes from revised estimates for professional services during the back half of the year, covering legal plus other accounting and consulting services. Non-cash interest expense for the second quarter totaled $5.4 million, and we expect it to stay around that same level across the two remaining quarters, adding up to roughly $20 million for 2025. Just a reminder that starting in 2025's first quarter, we began using equity method accounting for our investment in Gannett BioChem, a new portfolio company. With equity method accounting, we determine our non-cash gain or loss by looking at how our portion of Gannett BioChem's equity shifts each quarter. Our non-cash loss tied to this equity method investment was $2.4 million in 2025's second quarter, and for the full year of 2025 we continue to expect a non-cash loss of about $10 million; looking at our income statement, we hold no obligations to put cash into Gannett. As an equity investor, our net loss during the second quarter was $41.6 million, or $2.95 basic and diluted net loss per share. Once you strip out the non-cash loss from our equity method investment, our non-GAAP net loss came to $39.2 million, or $2.78 basic and diluted net loss per share. As I mentioned before, we now anticipate closing out the year with roughly $180 million to $185 million in cash and investments, and our cash runway now reaches into the first quarter of 2027. I'll have the operator open up the lines so we can take your questions.
Howard Robin
executiveHoward here. The first portion of that question is going to J. Z., and I'll handle the second portion. J. Z., over to you.
Jonathan Zalevsky
executiveYes. Thank you, Howard. Thank you, Chung. Regarding your initial inquiry, have we started interacting with the regulatory agencies? That process is currently underway. As I said before, our strategy involves an end of phase II meeting, which we plan to convene prior to the conclusion of this year. Right now, we are essentially preparing the request for that meeting, and the briefing package will be submitted, and the foundation of what we will cover there is, in fact, the trial design. Our fundamental approach for the trial design is that we anticipate having 2 monotherapy studies that are essentially the same in their structure, plus a long-term extension study that allows for the gathering of long-term safety information. For this division, there are several other studies that are mandated and are standard for each and every BLA submission for a novel molecule. Regarding those studies, as we noted earlier during this call, we recognize there is a considerable opportunity for REZPEG across multiple lines in atopic dermatitis. We possess very robust data in biologic-naive patients and have demonstrated that in our phase II-B results that you brought up. That will represent a significant share of our patient population. We also intend to enroll biologic-experienced patients in the trial. In that respect, akin to the types of studies that Amgen and Kyowa conducted with ROCA, where they merged both naive and experienced patients into a single study, we believe that was a highly efficient method, and our aim is to adopt that identical strategy and likewise have both patient groups in our phase III program, which would allow us to secure the broadest label when we proceed to register REZPEG. I believe that covers your questions concerning some of the health authority interactions and trial designs. Howard, I will hand it over to you regarding partnership and timing.
Howard Robin
executiveYes, of course. Thank you, J. Z. So, like we mentioned during the call, our goal is to finish the year with somewhere between $180 million and $185 million. We intend to have REZPEG ready for a phase III clinic launch in 2026. Our cash runway extends into 2027. At this moment, we aren't planning any extra financing. Several significant data catalysts lie ahead, and we are in active conversations with partners regarding possibly working together on REZPEG, which includes strategics along with financing partners. Some approaches involve teaming up with another company. Other approaches use non-dilutive financial strategies; we also possess additional sources of non-dilutive capital; for instance, we hold 3%- 4% of dapimab, which is UCB's phase III lupus drug. I believe there is, and we are definitely examining ways to monetize that asset. Many opportunities exist for us. What I would say is that at present we are involved in partnership talks. Understood. Many thanks, and congratulations once more on the progress. Thanks.
Yasmeen Rahimi
analystThanks, good afternoon everybody, and congrats on all the developments and the fantastic remarks. My question, I guess, is the following: with the next short-term data milestone being the AA readout that's coming up, J. Z., might you walk us through how you're thinking about what makes for a competitive product profile when it comes to moving into a later phase of development, and as well, once the top-line data comes out, will we be seeing any of those patients who continued into the longer extension, or is that something we shouldn't count on?
Jonathan Zalevsky
executiveI'll get back in line here. Yeah, absolutely. Thank you, Yaz. That's an excellent question. When it comes to alopecia, one key point is that there are currently no approved biologics for alopecia areata, and no therapy has demonstrated a lasting treatment benefit. JAKs are effective, though. In fact, just recently, Rinvoq shared what may be the best-in-class JAK inhibitor results for this condition, from the first of its phase lII trials that came out a few weeks ago. Still, its profile is well understood. This mechanism requires ongoing dosing. Once you halt the JAK inhibitor, patients shed whatever hair they might have regrown. You're taking on extra safety responsibility, and that's especially tough with this condition because a lot of patients are on the younger side and will be dealing with it for their whole lives. For us, the prospect of someone being on a JAK inhibitor chronically across a great many years is a hard one. In this phase II, the approach we took when designing the trial uses a primary endpoint built around the percent change in SALT scores relative to baseline. Although hitting certain JAK metrics isn't strictly something we have to do, those metrics are still something we rely on. When we're assembling the TPP we have in mind for this indication, they serve as highly valuable reference points. To give you a sense of what to watch for at that endpoint, with low-dose JAK you see roughly a 30% decrease in SALT score from baseline, and with the high dose it's around 40%. That's the neighborhood we want to land in. If REZPEG delivers the sort of scientific profile we believe this biology can support, then clearly we'd aim to exceed that. Naturally, we'll keep our eyes on the pivotal registrational endpoints too, since they'll tell us a lot as we move forward and think past the phase II-B trial in alopecia areata. In particular, SALT 20 and SALT 10 are the ones that matter most. When it comes to accepted thresholds, SALT 20 is what the FDA recognizes, while SALT 10 serves as Europe's standard. For the JAK inhibitors, the low dose achieves roughly 20% and 10% on SALT 20 and SALT 10 respectively, while the high dose reaches about 35% and 25%. Those figures, together with what Rinvoq has reported, are what we're measuring ourselves against. There's a lot of excitement on our side about the data set headed our way later this year. I'm genuinely enthusiastic about the prospect of advancing REZPEG into an additional dermatological indication — an area where we recognize that Tregs play a massive role, right down to the fundamental biology governing hair growth, and where we have a real shot at being the first biologic.
Yasmeen Rahimi
analystThanks a lot, J.Z.
Julian Harrison
analystHello, and thanks for taking my question. Congrats on everything that's happened lately; it's wonderful to hear what you're planning. Regarding adding biologic-experienced atopic derm into your initial registration program for REZPEG, could you remind us what gives you confidence that REZPEG will work in that segment?
Jonathan Zalevsky
executiveYes, absolutely. Thanks, Julia, for asking. You know, what's interesting is that we're generally observing several agents demonstrating activity among biologic-experienced patients. Correct, that's what we've been seeing. Let me give a few illustrations. Libre provided such an illustration. ROCA appears, you know, to provide that illustration as well. In our case, we hold this fundamental belief that our mechanism does not overlap with, get negated by, or run counter to any of the post-IL-13 type of biology. Take a patient whose disease presentation is more mixed, for instance TH2, yet with extra T helper endotypes fueling the inflammation. Clearly, when you use a TH2 inhibitory mechanism such as an IL-4/IL-13, the remaining portions of the immune system are, you know, left alone. We recognize that we possess broad capability to block various forms of polarized T cell inflammation. There's genuinely no further, you know, prior knowledge or scientific rationale for why an effect wouldn't exist. Plus, since we are an agonist rather than an antagonist agent, and a cellular agonist at that, it reassures us that REZPEG ought to show activity regardless of whether the patient is biologic-naive or experienced. Naturally, patients can fail those agents in numerous ways, be it a tolerability signal or a loss of efficacy signal. Once more, in either scenario, we believe REZPEG holds potential.
Julian Harrison
analystThat's quite useful. Thanks a lot.
Arthur He
analystHi there, good afternoon, Howard, along with the rest of the team. Nice work on the advances. I have one brief question regarding the possible pivotal trial for REZPEG in AD, specifically about the cohort of patients who've already been exposed to biologics. How are you thinking about prior biologic treatment? Will it lean heavily toward those newly experienced with biologics, or will you instead run something like a basket cohort of patients?
Jonathan Zalevsky
executiveYeah. Appreciate that, Arthur. Excellent question. We're aiming to kick off our initial phase III trial during the first half of next year. By then, the main approved mechanisms would fall into the IL-4 and IL-13 category. Correct; that covers dupixent, lebrikizumab, right, Adbry, tralokinumab too; plus nemolizumab has approval as an IL-31 antagonist. That one would likewise count as biologic-experienced. For us, though the OX40 class won't be approved yet, probably by the time we start, most likely the earliest player will get approval somewhere in that period. Clearly, not that many patients have used those medications so far, but even so, that group would similarly make up a biologic-experienced patient population. Hopefully that addresses your question.
Arthur He
analystThank you, J.Z.
Mayank Mamtani
analystHello Dean, I appreciate you fielding our questions, and congratulations on a highly productive second quarter within the phase III effort. I was curious what you anticipate regarding the primary endpoint of induction efficacy and how long therapy would last, given that peak EASI and itch efficacy aren't reached at 16 weeks. Also, the consideration you may be giving to obtaining the remedy efficacy signal. Could anything be gleaned from the OX40 trials that are somewhat pursuing a similar objective? I have a few follow-ups.
Jonathan Zalevsky
executiveYes, absolutely. Thank you, Mike. Something our phase II-B study, in our view, truly provided us with a clear grasp of is the dose level and the regimen we intend to advance into our phase III studies. Since our top line, we've already utilized the study's results to build a population PK model along with an exposure response model. As you're aware, those two are essential elements of the end of phase II meeting package that serve to justify the dose level for phase III. We're quite confident about that. We noted before, correct, that our study's design includes multiple portions where patients continue treatment for a longer duration past week 16. We're very enthusiastic about the data cut we discussed earlier on our call, since that genuinely begins to drill down into what those effects are and the possibility of deepening responses when patients receive treatment past 16 weeks. For instance, we know that among some contemporary phase III studies, a trend has emerged toward longer induction endpoints. We also sense that we haven't even yet reached or witnessed the maximum efficacy of REZPEG. We believe that's still unfolding. As individuals receive more treatment, there's a substantial chance we might observe deepening. As we proceed into our end of phase II meeting, we'll also clarify and propose how long our induction lasts and, naturally, the maintenance arms we're testing in phase II; at present those are both Q4 and Q12, but we'll also gain further information about how we wish to advance the maintenance regimen, so both the induction duration and then the maintenance portion of those studies; we're planning 52 week studies within our phase III program. Your other question concerned the remission potential. I want to begin by, you know, just reminding everyone that the phase II-B design consisted of a 16 week induction followed by a 36 week maintenance or escape, depending on how patients concluded their 16 week. There is a 52 week off drug follow up. What we want to do is give patients therapy for 12 months, then monitor them for 12 months while off the drug, so we can evaluate remission or look at how durable and stable the response is — or at minimum, how long the benefit persists once treatment ends. Our phase II trial should actually yield a data set even richer than what we got following the 12-week induction portion of the phase I-B trial. As for how we'd apply that in phase III, it will really resemble the approach you brought up. Treatment withdrawal is being done at various time points in both the Enlighten MAB studies and the rocatlumab studies, and we'd aim to take that kind of approach; say, one possibility would be to treat for 52 weeks and then, within our long-term extension, include a randomized withdrawal portion, which would let us measure both that potential for remission and longer-term therapy in a blinded, randomized withdrawal design.
Mayank Mamtani
analystThank you, that's quite useful, Jonathan Zalevsky. Perhaps we can remain on the same subject of what we've learned from OX40 — the alopecia data observed up to now might not reach the benchmarks you provided for JAK inhibitors, but I was simply wondering, since you sit somewhere in the middle in AD, whether that carries over into the alopecia trial, and then finally for Howard, is there anything new regarding the Lilly litigation, and given that the REZOLVE-AD results are now in hand, has anything shifted in your view of the outcome and the associated liabilities you may be asserting? Thanks for taking a question.
Howard Robin
executiveIf you'd like. J. Z., why don't you begin, and then I'll handle the Lilly question.
Jonathan Zalevsky
executiveYeah, absolutely — I'll begin with the alopecia. To start, keep in mind that our endpoint for alopecia is at 36 weeks, and we were just talking about dosing for a longer period past week 16. Please hold both of those points in your head; in alopecia areata, we believe there's a chance for a really thrilling result, and we treat the JAK inhibitor as the reference standard. No biologic has truly made a name for itself in this area, and we're quite enthusiastic about our mechanism being the one to do it; if anything, we view what we've learned from atopic derm as favorable for alopecia. Howard, over to you.
Howard Robin
executiveAll right. Yeah, allow me to. Clearly, that's not something we'll do. We absolutely cannot make any remarks regarding the Lilly lawsuit. I believe we remain strongly dedicated to seeing it through, given the REZPEG information we've shared and what continues to emerge. Our view is that this program holds considerable promise and will generate substantial value from other parties. Regarding the litigation, I'd say it truly will — let me phrase it this way, what we've observed from REZPEG up to now should benefit our case. I definitely don't think we're in a spot to address the details, except to state that we're extremely committed to pushing this forward, and we do feel Lilly harmed us considerably regardless. To illustrate, the product spent a few years delayed before reaching the market. You can work out what that translates to over the long run. On the whole, our stance is solid. We will see this lawsuit through until it concludes. I'd say we're happy with how things are progressing.
Mayank Mamtani
analystThanks for the additional detail, everyone, and thanks.
Cha Cha Yang
analystHello, is this coming through?
Jonathan Zalevsky
executiveYes.
Cha Cha Yang
analystAll right, fantastic. Hello, I'm Cha Cha Yang, filling in for Rogers Wong. I was wondering if you might share any updates regarding the studies you're conducting to gain a better understanding of the ISRs — whether from a mechanistic angle, or if you could update us on efforts toward creating strategies to reduce them once the product is commercialized.
Jonathan Zalevsky
executiveAbsolutely, yes. I appreciate that question, Cha Cha. Through our research, we've been evaluating ISR biology by way of several techniques. A particularly helpful one for us involves primary skin organoid cultures, which use skin taken during tummy tuck procedures. This is extremely handy since that skin comes from the abdominal region, and the abdomen is where we inject. Correct. Among the findings we've gathered thus far is that this is, as has been understood for quite some time, driven by an IL-2 effect. It's well established that IL-2 triggers injection site reactions. That finding emerged during the late 1980s and early 1990s, when subcutaneous experiments with the molecule first began. The pathways we observe being activated tie back to IL-2. For us, that's genuinely a strong finding, since it lets us replicate those pathways in the organoid culture; we're able to examine them both at the mRNA level and at the pathway level. This opens doors for us to be highly targeted in the sorts of mitigation strategies we might deploy, given that we can tell which pathways are active and can even pinpoint the cells doing the most signaling. One more key point for us is that we've been running the program essentially with drug supplied in a vial. At the study sites, the drug gets drawn up and then given to the patient subcutaneously by a healthcare practitioner. At launch, we'll introduce a product presentation consisting of a pre-filled syringe placed inside an auto injector. We're confident this will help, since it should truly standardize how the drug is administered — the depth of the needle, the speed, and the needle itself will be dry — along with everything else we're picking up from these biological strategies. We'll pursue all of that during the ongoing phase III program, and we intend to build those elements into the auto injector available when we launch.
Howard Robin
executiveI'd like to add something there as well. From a marketing perspective, I don't see it as an obstacle at all. As for patients, 2 withdrew from the trial because of reactions at the injection site. For most of them, these were mild to moderate. They cleared up on their own, and nobody discontinued the drug over them. Although a large number of patients did experience an injection site reaction, they might have had just 1 or 2, and then no additional reactions at the injection site. In some cases, months passed before a patient had one, then they had one, and after that none at all. You really need to grasp what actually took place with these injection site reactions. It's not the case that a big proportion of patients experience them with every single injection. That's simply not true; regardless, the majority were mild, and patients didn't appear bothered. When you consider the issues tied to IL-13 therapies, like conjunctivitis infections, those are honestly far more worrisome than mild to moderate injection site reactions that resolve on their own. I believe J.Z. raised a really strong point. An auto injector will take care of a great deal of that. There's a lot of — I don't want to call it sloppiness — but a lot of inconsistency in how patients give themselves the drug. They put it into a vial, the needle is wet, and so on. Auto injectors ought to fix quite a few of those problems; regardless, the level of ISRs we observed, I don't believe, is meaningful from a marketing standpoint.
Cha Cha Yang
analystAll right, thanks.
Alex Ramsey
analystHello, and thank you for letting us ask. I'm Alex Ramsey, filling in for Andy Shea from William Blair. I want to revisit the possible remitted impact of REZPEG when used for atopic dermatitis — this is a topic we've found intriguing. Maintenance results are due early next year, so what efficacy threshold or specific data points at that readout might hint at a remitted effect? That's the first part. Also, must we hold off until 2027 before we can judge whether this regimen offers that kind of edge? Second part: do you have any idea how much you'd need to suppress disease recurrence in order to reach a genuine remittive effect?
Jonathan Zalevsky
executiveAlex, thank you. Excellent questions. Let's take the first one — regarding remittive effect, everything we have from this portion of the phase II-B REZOLVE-AD trial remains on-treatment information. Patients who completed week 16 induction with an EASI-50 or higher advanced into the maintenance groups, where they continued at the same dose they'd received during induction, except the schedule changed to either monthly or every three months, and that continued for 36 weeks. What we present during the first quarter of next year will also be on-treatment information. I'll address your remittive question for part two shortly. To be precise, that Q1 2026 dataset is treatment data, though it will include a component with very infrequent dosing. Roughly half of those who went into maintenance will be receiving treatment every 12 weeks, so we'll be examining a very low dosing frequency and setting it against a Q4 week schedule. During this call, we've mentioned several times the possibility of responses growing deeper, and what we're most eager to assess in maintenance under continued dosing includes, for instance, among those who came in with an EASI 50 but lacked an EASI 75, what fraction went on to reach 75? And among those at EASI 75, how many progressed to 90, and so on? We'll also examine those who responded during week 16 induction to see how well that held up — meaning, with continued dosing, did the response persist or disappear? Those represent the two primary categories of analysis we'll focus on. Within the escape arm, we'll examine things such as the crossover group and similar factors once everybody is shifted to the higher dose. That subsequent portion truly speaks to duration and 52 weeks of treatment, which serves as a strong indicator for us regarding total treatment length. On your second question regarding the remitter effect—whether you have to get to a particular severity level for the best durability—I believe that is an excellent question. Of course, someone hitting EASI-75 versus someone hitting EASI-90 represents two distinct efficacy levels. That is a truly important thing to ask. Does an EASI-90 patient show more remission, or is it identical between an EASI-90 and an EASI-75 patient? The sole data we can really point to for that comes from our phase I. During phase one, we observed that individuals with an IGA response at week 12 and an IGA response at week 48, despite having halted treatment at week 12, showed roughly 80% IGA maintenance and roughly 70% EASI-75 maintenance over that six-month horizon during the six-month off-drug period. That data could suggest there might be a somewhat better remitted effect among those with deeper disease. I think you would truly require far more data to be certain about that. I am eager to see some of the other mechanisms we will attempt to address that with as well, like the OX40 mechanisms, both of which are incorporating treatment-free intervals into their phase three programs. Thank you for your question.
Alex Ramsey
analystThanks. That's really useful. I truly value the extra detail.
Jessica Fye
analystHi everyone, good evening. I appreciate you fielding my questions. Regarding REZPEG for AD, could you share how confident you feel about the statistical power for the maintenance stage of that study, given the participants who dropped out during induction? My understanding is you'd accounted for a certain amount of attrition. I just want reassurance that you remain comfortable with the powering for maintenance. Also, when you presented the top-line induction results in AD, I believe you were comparing against OX40. Could you take a moment to explain why you consider that the appropriate comparator for this product? Thank you.
Jonathan Zalevsky
executiveOf course. Yes. Thanks, Jess. To start, as we announced in June, 190 individuals entered the maintenance arm. We view that as a solid population. In fact, it matches precisely what we projected would cross over. Those projections drew on prior phase II trials and comparable phase II patient groups, comparable statistical approaches employed in induction, and naturally, largely informed by our phase I findings and phase I outcomes. We're quite pleased with how many individuals entered the maintenance stage. Exactly as you suggest, since we intended to evaluate two dosing regimens, essentially you assign them one to one. Among those who received placebo, there were a few, correct? It was under 30%. Those individuals remain on placebo, while all the rest receive REZPEG, correct, and afterward they get assigned one to one to either a monthly schedule or a schedule of once every three months; this aligns perfectly with our study design, and we feel quite good about it. On your following question regarding comparison with OX40, it proved highly enlightening for us once we began examining the phase III I trials in close detail — the trial design, the patient groups, and other factors. Upon reviewing that, we observed that regulators keep pushing you toward increasingly stringent statistical frameworks as more and more competitors advance through later-stage clinical development. That's typical; every regulator tends to operate that way. It genuinely raises the standard. We observed that our trial design, our statistical approach, even our sample sizes and patient groups, and even geographic reach, were far more comparable to the OX40 phase II-B trials. The remaining trials, such as Dupia, well, that was conducted a great many years back, more than 10 years ago. Quite a distinct patient group. Trelo, which followed, the same. A markedly distinct patient group. Additionally, when examining novel mechanisms, for us, viewing REZPEG as an entirely new and first-in-class mechanism in atopic derm. Considering the OX40 class, which was novel compared with the IL-13s. We made that a focus among our comparison areas for those reasons. Naturally, the full picture matters too, which is the reason we listed every approved agent, along with those in phase III.
Jessica Fye
analystThanks.
Howard Robin
executiveThanks, Crystal. As we wrap up, I'd like to express gratitude to both the new and existing investors who backed the capital raise we completed recently; your support as shareholders means a great deal to us. My thanks also go out to our team members for the commitment and truly tireless effort they bring. We're eager to share further data updates before this year ends and to begin discussions with regulators regarding our phase III program. We appreciate your presence here today, so please keep watching for more.
Moderator
operatorThat wraps up the call for today. We appreciate everyone joining us. You're free to drop off now. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.